# Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

> **NCT01640301** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia
- Donor
- Hematopoietic Cell Transplant Recipient
- HLA-A*0201 Positive Cells Present
- Recurrent Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** WT1-Sensitized Allogeneic T-Lymphocytes

## Key facts

- **NCT ID:** NCT01640301
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-06
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-03-20
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640301, "Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01640301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*